Drug intelligence / Profile preview

ABD

Development stage: Preclinical
Lead developer: ARTBIO
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ABD is an alpha radioligand therapy (ART) being developed by ARTBIO for the treatment of triple-negative breast cancer (TNBC) and head and neck squamous cell carcinoma (HNSCC). The drug consists of a targeting ligand labeled with the alpha-emitting isotope Lead-212 (212Pb). This approach is designed to deliver potent, localized radiation to cancer cells, inducing double-stranded DNA breaks while sparing healthy tissue. ABD is currently in the discovery stage and is part of ARTBIO's proprietary pipeline of 212Pb-based radiopharmaceuticals. The molecular target of the ligand remains undisclosed.

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on ABD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABD.

Explore the full profile